

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Elisabeth M. Bock, et al.

Examiner: J. Andres

Serial No.: 09/781,509

Art Unit: 1646

Filed: February 12, 2001

Docket: 12754A

For: NEUROGENIC COMPOSITIONS
AND METHODS

Commissioner for Patents
United States Patent and Trademark Office
Alexandria, Virginia 22313-1450

DECLARATION OF DR. EUGENE LUKANIDIN
UNDER 37 C.F.R. §1.132

Sir:

I, Eugene Lukanidin, hereby declare as follows:

1. I am one of the co-inventors of the above-identified application.
2. I hold a Bachelor of Science (M.D.) Degree in 1966 and a Doctorate Degree in 1978. My research interest is in the field of Molecular and Cancer Biology, and I have authored more than 100 publications in this field. Currently I am a Professor at the Department of Molecular Cancer Biology, Institute of Cancer Biology, Danish Cancer Society. A true and correct copy of my curriculum vitae is attached hereto as Exhibit A.
3. I have reviewed the above-identified application (hereinafter referred to as '509 application), and I am familiar with the subject matter therein. Specifically, the '509 application provides the unique recognition that Mts1 proteins form multimers in physiological solutions and

that the neurogenic activity of Mts1 proteins is associated with the multimeric forms of the protein, as opposed to the monomeric and dimeric forms of the protein. Accordingly, the '509 application is directed to an isolated multimeric Mts1 protein complex which contain three or more molecules of an Mts1 protein.

4. I have also read the Final Action dated May 19, 2003, issued in the '509 application. It is my understanding that the Examiner holds the opinion that U.S. Patent No. 5,801,142 to Zain et al. ("the '142 patent") teaches an isolated trimeric form of human Mts-1. Specifically, referring to column 38, lines 50-52 and Figure 15 of the '142 patent, the Examiner states that the '142 patent teaches that the mouse Mts1 protein migrates on a gel with a molecular weight of 10-12 kD. Further referring to Figure 16 and column 38, lines 53-58 of the '142 patent, the Examiner states that the '142 patent also teaches that the human Mts1 protein has an apparent molecular weight of 27 kD. The Examiner reasons that, since there is a difference of only 7 amino acids between the mouse and human sequences, it appears that the 27 kD band identified in Figure 16 of the '142 patent represents a trimeric form of human Mts-1.

5. I have reviewed the '142 patent in its entirety. It is my scientific opinion that the '142 patent does not teach an isolated trimeric form, or any other multimeric form, of Mts-1, as disclosed and claimed in the '509 application.

6. The experiment underlying Figure 16 of the '142 patent is described at column 38, lines 6-13. Specifically, serum samples were obtained from normal women and patients with breast carcinomas or advanced malignant lymphomas. 150 µg of each serum sample was run on a 12% SDS-PAGE gel. The proteins were transferred to PVDF membranes and the membranes were probed with a 1:1000 dilution of α -mts1 and then with a 1:1000 dilution of the secondary antibody (rabbit anti-chicken IgG-HRP). The reaction was developed with a DAB solution. Figure 16 illustrates that a protein band with an apparent molecular weight of approximately 27 kD could be detected in serum from a patient with metastatic breast cancer as well as two patients with metastatic lymphomas, but not in serum from a normal patient or patients with non-

metastatic breast cancer or non-metastatic lymphomas. The 27 kD band apparently contains denatured human Mts1 polypeptide, as the band was detected by α -mts1 antibodies and disappeared (i.e., competed off) when the Western blot was probed with α -mts1 antibodies in the presence of free mts-1 protein. See column 38, lines 64-67 of the '142 patent.

7. It is my scientific opinion that, because the serum samples were run on a 12% SDS-PAGE gel, the 27 kD band in Figure 16 of the '142 patent merely represents an aggregate of denatured proteins. The aggregate could be an aggregate containing one or more denatured Mts1 polypeptides, or an aggregate containing a denatured Mts1 polypeptide and other polypeptides present in the serum sample. In contrast to an aggregate of denatured polypeptides of the '142 patent, the multimeric Mts1 complex, as disclosed and claimed in the '509 application, is composed of undenatured Mts1 proteins and has neurogenic activity. In addition, the multimeric Mts1 complex, as disclosed and claimed in the '509 application, appears as an 11 kD band on an SDS-PAGE (i.e., under denaturing conditions). See Figure 11D and page 37, lines 25-30 of the '509 application.

8. It is also my scientific opinion that, regardless of the nature of the 27 kD band, one skilled in the art would not consider the Western blot analysis depicted in Figure 16 of the '142 patent to be an isolation or purification of the 27 kD polypeptide. As described in the '142 patent, human serum samples were run on the SDS-PAGE before the Western blot analysis. The 27 kD band, which apparently contained human Mts1, was merely detected as a component among numerous proteins present in the serum sample. In this instance, the SDS-PAGE coupled with the Western blot analysis, was merely a procedure for detection of the Mts1 material. There was simply no recovery of the 27 kD material, i.e., no isolation of the 27 kD material, away from other components in the serum sample. In contrast, the multimeric Mts-1 complex, as disclosed and claimed in the '509 application, is in an isolated form, and can be isolated by an appropriate chromatography procedure, as exemplified in Example 3, the paragraph bridging pages 36-37 of the '509 application.

9. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that those statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

By: Eugene Lukasidio 
Dated: 17/09/03

CURRICULUM VITAE

Name: Eugene M. Lukanidin
Title: Professor, Ph.D., M.D.
Date of Birth: May 14, 1942
Place of Birth: Kuybishev, USSR
Nationality: Russian

Address: Danish Cancer Society,
Institute of Cancer Biology,
Dept. of Molecular Cancer Biology,
Strandboulevarden 49, opg. 4.3.
DK-2100 Copenhagen, Denmark
Telephone: +45 35 25 73 13
Fax: +45 35 25 77 21
E-mail: el@cancer.dk

Affiliation position: Head of Department, (Dept. of Molecular Cancer Biology),
Institute of Cancer Biology, Danish Cancer Society.
Member of Russian Academy of Natural Sciences, Moscow 1991.

Education:

1966 M.D. - Medicine. Second Moscow Medical Institute of Medicine.
1969 Ph.D. - Biology/Mol.Biol. Institute of Molecular Biology, Moscow.
1978 D.Sc. - Biology/Mol.Biol. Institute of Molecular Biology, Moscow.

Professional experience:

1966 - 1969 Postgraduate Student, Institute of Molecular Biology, Moscow.
1969 - 1976 Junior Scientist, Institute of Molecular Biology, Moscow.
1976 - 1983 Senior Scientist, Institute of Molecular Biology, Moscow.
1983 - 1990 Leading Scientist, Institute of Molecular Biology.
1990 - 1992 Head of the Laboratory of Molecular Genetics of Cancer, Institute of
Gene Biology, Moscow.
1992 - present Head of Department of Molecular Cancer Biology, Institute of
Cancer Biology, Danish Cancer Society, Copenhagen.

Fellowships:

1968 - 1969 The Norwegian Institute for Cancer Research - Visiting Scientist
(Laboratory of Biochemistry - Dr. A. Phil).
1975 - 1976 Cold Spring Harbor Laboratory - Visiting Scientist (Laboratory of
DNA Tumor Viruses - Dr. J. Sambrook).
1983 M.I.T. Cancer Research Center - Visiting Scientist (Laboratory of
Molecular Oncology - Dr. R. Weinberg).

Eugene Lukanidin: List of publications 1967 - 2003:

(Only papers published in English)

Samarina OP, Georgiev GP, Lukanidin EM: On the structural organization of the nuclear complexes containing mRNA. **BBA**, 142 : 561-564, 1967.

Samarina OP, Molnar J, Bruskov, I, Lukanidin EM, Krichevskaya AA: Reversible dissociation of nuclear ribonucleic-protein particles containing mRNA into RNA and protein. **J. Mol. Biol.**, 27 : 187-191, 1967.

Samarina OP, Lukanidin EM, Krichevskaya AA, Mantieva VL, Georgiev GP: Nuclear complexes containing D-RNA and their possible role in the messenger transfer. In: **Protein Biothesis**. Szafranki P et al (eds), 111-117, 1968.

Lukanidin EM, Samarina O, Molnar J, Georgiev GP: Structural organization of nuclear complexes containing DNA-like RNA. **J. Mol. Biol.**, 33 : 251-263, 1968.

Georgiev GP, Lukanidin EM, Ryskov AP: On the mechanism of biosynthesis and transport of messenger RNA in eukaryotes. **FEBS symposium**, 24 : 55-76, 1972.

Lukanidin EM, Zalmanzon ES, Komoromi L, Samarina OP, Georgiev GP: Structure and function of informers. **Nature New Biol.**, 238 : 193-197, 1972.

Lukanidin EM, Olsnes S, Phil A: Antigenic difference between informers and protein bound to polysomal mRNA from rat liver. **Nature New Biol.**, 240 : 90-92, 1972.

Lukanidin EM, Samarina OP, Georgiev GP: Ribonucleo-protein particles containing mRNA and pre-mRNA. **Karolinska Symposium**, N6 : 130-167, 1973.

Lukanidin EM, Samarina OP, Ryskov AP, Georgiev GP: On the regulation of pre-mRNA biosynthesis and transport. IN: **Control of Transcription**. Biswas, Mendel, Stevens, Cohn (eds). Basic Life Science, Plenum Press, N3 : 303-315, 1974.

Zalmanzon ES, Lukanidin EM, Mikhailova L: The nature of nuclear ribonucleo-protein particles containing virus-specific RNA. **Mol. Biol. Reports**. No.1 : 269-273, 1974.

Fey G, Sambrook J, Lukanidin EM, Levis J: Adenovirus/SV40 hybrida II. Expression of their SV40 sequences. SV, Py and AD. **Cold Spring Habor**, 8, 1976.

Frolova E, Zalmanzon E, Lukanidin EM, Georgiev GP: Studies on the transcription of viral genome in Ad.5 transformed cells. **Nucleic Acids Res.**, 5 : 1-11, 1976.

Aitkozhina NA, Kulguskin VV, Lukanidin EM, Georgiev GP: The isolation informofers free from dRNA. **FEBS Letters**, 19 : 101-104, 1977.

Lukanidin EM, Georgiev GP, Williamson R: A comparative study of the protein components of nuclear and polysomal messenger RNP. **FEBS Letters**, 19 : 152-156, 1977.

Lukanidin EM, Noll F: Species specificity of information. **Mol. Biol. Rep.**, 3 : 339, 1977.

Lukanidin EM, Noll F: Immuno-chemical assay for information in cytoplasmic polysomes. **Mol. Biol. Rep.**, N3 : 347, 1977.

Galloway D, Lukanidin EM, Topp W, Sambrook J: Transformation of rat cells by the hybrid virus Ad HEY. **J. Virology**, 1977.

Grozicker, Lukanidin EM, Lewis J, Galloway D, Sambrook J: Revertants of host range mutants of Ad-ND, SV40, Py and Ad. **Cold Spring Habor**, 92, 1977.

Frolova E, Zalmanzon E, Lukanidin EM: Transcription of fragments of viral DNA in AD-5 transformed cell lines SV40, Py and Ad. **Cold Spring Habor**, 78, 1977.

Grigorian MS, Chumakov P, Lukanidin EM, Georgiev GP: SV40 gene expression in transformed cells SV40, Py and Ad. **Cold Spring Habor**, 103, 1977.

Sambrook J, Hassel J, Lukanidin EM, Zain S: Adenovirus-SV40 hybrids 1. New adenovirus genome that contain SV40 sequences. SV40, Py and Ad. **Cold Spring Habor**, 6, 1977.

Kulguskin V, Georgiev GP, Lukanidin EM: Free informofers and reconstruction of 30S RNP. **Cold Spring Habor Quant. Biol.**, 42 : 911, 1977.

Hassel S, Lukanidin EM, Sambrook J: The structure and expression of the defective adenovirus-2/Simian virus 40 hybrids. **J. Mol. Biol.**, 120 : 263, 1978.

Galloway D, Toop W, Lukanidin EM, Sambrook J: Transformation of rat cells by the hybrid virus ad HEY. **J. Gen. Virol.**, 42 : 339-356, 1979.

Grigorian MS, Kramerov DA, Lukanidin EM: Initiation point for DNA replication in mammalian cells. SV40, Py and Ad. **Cold Spring Habor**, 43, 1980.

Grigorian MS, Chumakov P, Lukanidin EM: Transcription of SV40 DNA in transformed rat cells. **Cold Spring Habor Symposium Quant. Biol.**, 44 : 77, 1980.

Lukanidin EM, Kulguiskin VV, Krichevskaya AA, Georgiev GP: Studies on dissociation and reassociation of nuclear 30S RNP particles containing pre-mRNA. **BBA**, 609 : 40, 1980.

Georgiev GP, Ilyin YV, Chemeliauskaitė VG, Ryskov AP, Kramerov DA, Skryabin KG, Krayev AS, Grigorian MS, Lukanidin EM: Mobile dispersed genetic elements and other middle repetitive DNA sequences in the genome of *Drosophila* and mouse. Transcription and biological significance. **Cold Spring Habor, Quant. Biol.**, 45, 641-654, 1981.

Razin SV, Kekelidze MG, Lukanidin EM: SV40 t-antigen binding to a mouse DNA containing sequences of homology to SV40 origin of replication. SV40, Py and Ad. **Cold Spring Habor**, 1982.

Georgiev GP, Kramerov DA, Ryskov AP, Lukanidin EM, Skryabin KG: dispersed repetitive sequences in eukaryotic genomes and their possible biological significance. **Cold Spring Habor Quant. Biol.**, 47 : 1109-1021, 1983.

Tulchinsky EM, Kramerov DA, Grigorian MS, Revazova EM, Lukanidin EM: Transcription of the transposable elements in mouse normal and tumor tissue. **ETVG Meeting**, 1984.

Ryskov Ap, Kramerov DA, Ivanov P, Lukanidin EM, Samarina OP: Different types of repetitive sequences in mouse genome. **Curr. Trends in Life Science. XII Biological Micromolecules**, 163-173, 1985.

Grigorian MS, Kramerov DA, Tulchinsky EM, Revazova ES, Lukanidin EM: Activation of putative transposition intermediate formation in tumor cells. **EMBO J.**, 4 : 2209-2215, 1985.

Razin SV, Kekelidze MG, Lukanidin EM, Scherrer K, Georgiev GP: replication origins are attached to the nuclear skeleton. **Nucleic Acids Res.** 14: 8189-8207, 1986.

Tulchinsky EM, Grigorian MS, Lukanidin EM: Closed circular DNA of transposable elements of the mouse genome. Role of the reverse transcriptase in their amplification. **XVIII Meeting of the European Tumor Virus Group**, Dresden, DDR, 1987.

Lukjanova TI, Rebizova TV, Revazova ES, Lukanidin EM: Separation of the pore-forming and cytotoxic factor. **FEBS Letters**, 226 : 261-264, 1988.

Ebralidze AK, Tulchinsky EM, Grigorian MS, Afanasyeva A, Senin V, Lukanidin EM: Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca^{2+} -binding protein family. **Genes Develop.**, 7 : 1086-1092, 1989.

Tulchinskii EM, Ebralidze AK, Grigorian MS, Milshechina NV, Lukanidin EM: Structure of the mts 271 gene, coding a new calcium-binding protein. **Genetika**, 25(7) : 1150-1159, 1989.

Chertov Olu, Krasnoselskii AL, Lukanidin EM, Sashchenko LN, Gnuchev NV: Isolation of a cytotoxic factor from the blood serum of athymic rats. **Bulleten Eksperimentalnoi Biologii I Meditsiny**, 107(3) : 329-331, 1989.

Tulchinsky EM, Grigorian MS, Ebralidze AK, Milshina N, Lukanidin EM: Structure of gene mts1 transcribed in metastatic mouse tumors. **Gene**, 87 : 219-223, 1990.

Sashchenko LP, Gnuchev NV, Kirillova MA, Luk'yanova TI, Rebizova TV, Chertov OYu, Lukanidin EM: Effect of antibodies to granular perforin and calmodulin on the activity of natural killer cytotoxic factor. **Biomedical Science**, 1(3) : 291-294, 1990.

Tulchinsky EM, Ford ML, Kramerov D, Reshetnyak E, Grigorian MS, Zain S, Lukanidin EM: Transcriptional analysis of the mts1 gene with specific reference to 5'flanking sequences. **Proc Natl Acad Sci. USA**, 89 : S146-S150, 1992.

Tulchinskii EM, Kramerov DA, Gural NI, Grigorian MS, Reshetniak Elu, Lukanidin EM: Characteristics of a positive regulatory element in the first intron of the mts1 gene. **Genetika**, 28(10) : 29-39, 1992.

Tulchinskii EM, Kramerov DA, Gural NI, Grigorian MS, Reshetniak Elu, Lukanidin EM: Structural and functional analysis of the promoter region of the mts1 gene. **Genetika**, 28(8) : 22-35, 1992.

Lukanidin EM et al: Functional changes in lymphokine-activated lymphocytes depending in the incubation time with interleukin-2. **Doklady Akademii Nauk**, 324 : 475-479, 1992.

Cardenas MA, Vorovich MF, Ebralidze AK, Chertov OIU, Lukanidin EM: Preparation of recombinant metastasin and characteristics of it. *Bioorganicheskaya Khimiia*, 19 : 420-426, 1993.

Tulchinsky E, Kramerov D, Ford M, Reshetnyak E, Lukanidin EM, Zain S: Characterization of a positive regulatory element on the mts1 gene. *Oncogene*, 8 : 79-86, 1993.

Grigorian, M, Tulchinsky E, Zain S, Ebralidze A, Kramerov D, Krajjevska M, Georgiev G, Lukanidin E: The mts1 gene and control of tumor metastasis. *Gene*, 135 : 229-238, 1993.

Grigorian MS, Zain S, Georgiev GP, Lukanidin EM: Role of mts1 gene in metastatic process. *Proc. Natl. Acad. Sci. (Russia)*, 342 : 574-579, 1993.

Grigorian M, Tulchinsky E, Burrone O, Tarabykina S, Georgiev G, Lukanidin E: Modulation of mts1 expression in mouse and human normal and tumor cells. *Electrophoresis*, 15 : 463-468, 1994.

Krajjevska M, Neira M, Ambartsumian N, Georgiev GP, Lukanidin E: Non-muscle myosin as a possible target for protein encoded by metastasis-related mts1 gene. *J. Biol. Chem.*, 269 : 19679-19682, 1994.

Tulchinsky E, Grigorian M, Tkatch T, Georgiev G, Lukanidin E: Transcriptional regulation of the mts1 gene in human lymphoma cells: the role of DNA-methylation. *Biochem et Biophys Acta*, 1261 : 243-248, 1995.

Ambartsumian N, Tarabykina S, Grigorian M, Tulchinsky E, Hulgaard E, Georgiev G, Lukanidin E: Characterization of two splice variants of metastasis-associated human mts1 gene. *Gene*, 159 : 125-130, 1995.

Krajjevska MV, Vorovich MF, Georgiev GP, Lukanidin EM: Mts1 protein in the cytoplasm of metastasizing tumors. *Dokl Akad Nauk*, 342 : 259-261, 1995.

Ambartsumian N, Tarabykina S, Grigorian M, Tulchinsky E, Hulgaard E, Georgiev G, Lukanidin E: Expression of splice variants of mts1 gene in human normal and tumor cells. *Genetika*, 9 : 125-130, 1995.

Tarabykina S, Ambartsumian N, Grigorian M, Georgiev G, Lukanidin E: Activation of mts1 transcription by insertion of a retrovirus-like IAP element. *Gene*, 168 : 151-155 1996.

Tulchinsky E, Georgiev G, Lukanidin E: Novel AP-1 binding site created by DNA methylation. *Oncogene*, 12 : 1737-1745, 1996.

Grigorian M, Ambartsumian N, Lykkesfeldt A, Bastholm L, Elling F, Georgiev G Lukanidin E: Effect of mts1 (S100A4) expression on the progression of human breast cancer cells. *Int. J. of Cancer*, 67 : 831-841, 1996.

Mælandsø GM, Hovig E, Skrede M, Engebråten O, Flørenes VA, Grigorian M, Lukanidin E, Scanlon KJ, Fodstad Ø: Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts1)ribozyme. *Cancer Research*, 56 : 5490-5498, 1996.

Lukanidin E: Metastasis-related mts1 gene. In: *Current topics in microbiology and immunology: Attempts to understand metastasis formation II*. Günthert U and Birchmeier W (eds), Springer Verlag, Berlin, Germany, 213: II, 171-195, 1996.

Ambartsumian N, Grigorian MS, Fossar Larsen I, Karlstrøm O, Sidenius N, Rygaard J, Georgiev G, Lukanidin E: Metastasis of mammary carcinomas in GRS/A hybrid mice transgenic for the mts1 gene. *Oncogene* 13 : 1621-1630, 1996.

Astafieva I, Maksimova I, Lukanidin E, Alakhov V, Kabanov A: Enhancement of the polycation-mediated DNA uptake and cell transfected with pluronic P85 block copolymer. *FEBS letters*, 389 : 278-280, 1996.

Krajjevska M, Grigorian M, Ambartsumian N, Georgiev G, Lukanidin E: Interaction of metastasin1 with nonmuscle myosin heavy chain. *Mol. Biol. (Moscow)*, 30 : 102-105, 1996.

Tulchinsky E, Prochortchouck E, Georgiev G, Lukanidin E: A Kappa related binding site is an integral part of the mts1 gene composite enhancer element located in the first intron of the gene. *J. Biol. Chem.*, 272 : 4828-4835, 1997.

Cohn MA, Kramerov D, Hulgaard EF, Lukanidin E: The differentiation antigen Ly-6E.1 is expressed in mouse metastatic tumor cell lines. *FEBS Letters*, 403: 181-185, 1997.

Georgiev GP, Kiselev SL, Lukanidin EM: Tumor progression and metastasis. In *Genome structure and function*. Nicolini C (ed), Kluwer Academic Publishers, Netherlands, 217-237, 1997.

Klingelhöfer J, Ambartsumian N, Lukanidin E: Expression of the metastasis-associated mts1 gene during mouse development. *Developmental Dynamics*, 210, 87-95, 1997.

Dukhanina EA, Dukhanin AS, Lomonosov M, Lukanidin EM, Georgiev GP: Calcium-binding characteristics and conformational changes in metastasin, a member of S-100 protein family. **Biochemistry (Moscow)**, 62, 621-628, 1997.

Dukhanina EA, Dukhanin AS, Lomonosov M, Lukanidin EM, Georgiev GP: Spectral studies on the calcium-binding properties of Mts1 protein and its interaction with target protein. **FEBS Letters**, 410, 403-406, 1997.

Christensen C, Klingelhöfer J, Tarabykina S, Hulgaard E, Kramerov D, Lukanidin E: Identification of a novel semaphorin, M-semaH, in metastatic mouse tumor cell lines. **Cancer Research**, 58, 1238-1244, 1998.

Kiselev SI, Kustikova Os, Korobko EV, Prokhortchouck EB, Kabishev AA, Lukanidin EM, Georgiev GP: Molecular cloning and characterization of the mouse tag7 gene encoding a novel cytokine. **J. Biol. Chem.** 273, 18633-18639, 1998.

Prokhortchouck EB, Prockhorthchouck AV, Rouzov AS, Kiselev SL, Lukanidin EM, Georgiev GP: A minisatellite "core" element constitutes a novel, chromatin-specific activator of mts1 gene transcription. **J. Mol. Biol.**, 280, 227-36, 1998.

Krajewska M, Tarabykina S, Bronstein I, Maitland N, Lomanosov M, Hansen K, Georgiev G, Lukanidin E: Metastasis associated Mts1 (S100A4) protein modulates protein kinase C phosphorylation of the heavy chain of nonmuscle myosin. **J. Biol. Chem.** 273, 9852-9856, 1998.

Kustikova O, Kramerov D, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E: Fra-1 induces morphological transformation and increases in vitro invasiveness motility of epithelioid adenocarcinoma cells. **Mol. Cell Biol.**, 18, 7095-7105, 1998.

Keirsebilck A, Bonné S, Bruyneel E, Vermassen P, Lukanidin E, Mareel M, van Roy, F: E-Cadherin and metastasin (mts-1/S100A4) expression levels are inversely regulated in two tumor cell families. **Cancer Research**, 58, 4587-4591, 1998.

Lukanidin E: Nucleic acid encoding human Mts1 protein. U.S. patent no: 5.798.257, issued 1998.

Lukanidin E: Human Mts1 protein. U.S. patent no: 5.801.142, issued 1998.

Lukanidin E: Methods of diagnosing metastatic cancer with Mts1 protein. U.S. patent no: 5.801.142, issued 1998.

Hulgaard E, Christensen C, Cohn M, Klingelhöfer J, Grigorian M, Kramerov D, Lukanidin E: Isolation and characterization of novel metastasis related genes. In: **NATO Life Science series. vol. Intermolecular cross-talk in tumor metastasis**. Skouteris GG, Nicolson GL (editors). p. 11-27, 1999.

Krajewska M, Klingelhöfer J, Tarabykina S, Ambartsumian N, Lukanidin E: Biological properties and functional role of metastasin, a protein product of the metastasis related gene mts1, in tumor malignancy. In: **NATO Life Science series. vol. Intermolecular cross-talk in tumor metastasis**. Skouteris GG, Nicolson GL (editors). p. 29-42, 1999.

Ambartsumian N, Klingelhöfer J, Grigorian M, Karlstrøm O, Sidenius N, Lukanidin E: Tissue-specific post-transcriptional down-regulation of expression of the *S100A4(mts1)* gene in transgenic animals. **Invasion and Metastasis**, 18, 96-104, 1999.

Kozlova EN, Lukanidin E: Metastasis-associated mts1 (S100A4) protein is selectively expressed in white matter astrocytes and is up-regulated after peripheral nerve or dorsal root injury. **Glia**, 27, 249-58, 1999.

Moroz OV, Antson AA, Dodson GG, Wilson KS, Skibshøj I, Lukanidin EM, Bronstein IB: Crystallisation and preliminary X-ray diffraction analysis of human calcium-binding protein S100A12. **Acta Crystallography**, in press, 1999.

Tarabykina S, Krajewska M, Scott DJ, Hill TJ, Lafitte D, Derrick PJ, Dodson GG, Lukanidin E, Bronstein I: Heterocomplex formation between metastasis-related protein S100A4 (Mts1) and S100A1 as revealed by the yeast two-hybrid system. **FEBS Lett.** Jun 23;475(3):187-91. 2000

Novitskaya V, Grigorian M, Krajewska M, Tarabykina S, Bronstein I, Berezin V, Bock E, Lukanidin E: Oligomeric forms of the metastasis-related Mts1 (S100A4) protein stimulate neuronal differentiation in cultures of rat hippocampal neurons. **J Biol Chem.** Dec 29;275(52):41278-86. 2000

Georgiev GP, Lukanidin EM. Mts1 protein and control of tumor metastasis Mol Biol (Mosk). Sep-Oct;34(5):727-30. 2000

Kriajevska M, Bronstein IB, Scott DJ, Tarabykina S, Fischer-Larsen M, Issinger O, Lukanidin E. Metastasis-associated protein Mts1 (S100A4) inhibits CK2-mediated phosphorylation and self-assembly of the heavy chain of nonmuscle myosin. *Biochim Biophys Acta*. Dec 20;1498(2-3):252-63, 2000

Moroz OV, Antson AA, Murshudov GN, Maitland NJ, Dodson GG, Wilson KS, Skibshoj I, Lukanidin EM, Bronstein IB. The three-dimensional structure of human S100A12. *Acta Crystallogr D Biol Crystallogr*. Jan;57(Pt 1):20-9. 2001

Tarabykina S, Scott DJ, Herzyk P, Hill TJ, Tame JR, Kriajevska M, Lafitte D, Derrick PJ, Dodson GG, Maitland NJ, Lukanidin EM, Bronstein IB. The dimerization interface of the metastasis-associated protein S100A4 (Mts1): in vivo and in vitro studies. *J Biol Chem*. Jun 29;276(26):24212-22. 2001

Grigorian M, Andresen S, Tulchinsky E, Kriajevska M, Carlberg C, Kruse C, Cohn M, Ambartsumian N, Christensen A, Selivanova G, Lukanidin E. Tumor suppressor p53 protein is a new target for the metastasis-associated Mts1/S100A4 protein: functional consequences of their interaction. *J Biol Chem*. Jun 22;276(25):22699-708. 2001

Ambartsumian N, Klingelhofer J, Grigorian M, Christensen C, Kriajevska M, Tulchinsky E, Georgiev G, Berezin V, Bock E, Rygaard J, Cao R, Cao Y, Lukanidin E. The metastasis-associated Mts1(S100A4) protein could act as an angiogenic factor. *Oncogene*. Aug 2;20(34):4685-95. 2001

Cohn MA, Hjelmsø I, Wu LC, Guldberg P, Lukanidin EM, Tulchinsky EM. Characterization of Sp1, AP-1, CBF and KRC binding sites and minisatellite DNA as functional elements of the metastasis-associated mts1/S100A4 gene intronic enhancer. *Nucleic Acids Res*. Aug 15;29(16):3335-46. 2001

Mikkelsen SE, Novitskaya V, Kriajevska M, Berezin V, Bock E, Norrild B, Lukanidin E. S100A12 protein is a strong inducer of neurite outgrowth from primary hippocampal neurons. *J Neurochem*. Nov;79(4):767-76. 2001

Kriajevska M, Fischer-Larsen M, Moertz E, Vorm O, Tulchinsky E, Grigorian M, Ambartsumian N, Lukanidin E. Liprin beta 1, a member of the family of LAR transmembrane tyrosine phosphatase-interacting proteins, is a new target for the metastasis-associated protein S100A4 (Mts1). *J Biol Chem*. Feb 15;277(7):5229-35. 2002

Moroz OV, Antson AA, Dodson EJ, Burrell HJ, Grist SJ, Lloyd RM, Maitland NJ, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB. The structure of S100A12 in a hexameric form and its proposed role in receptor signalling. *Acta Crystallogr D Biol Crystallogr*. Mar;58(Pt 3):407-13. 2002

Kozlova EN, Lukanidin E. Mts1 protein expression in the central nervous system after injury. *Glia*. Mar 15;37(4):337-48. 2002

Neumark E, Cohn MA, Lukanidin E, Witz IP, Ben-Baruch A. Possible co-regulation of genes associated with enhanced progression of mammary adenocarcinomas. *Immunol Lett*. Jun 3;82(1-2):111-21. 2002

Andersen H, Mahmood S, Tkach V, Cohn M, Kustikova O, Grigorian M, Berezin V, Bock E, Lukanidin E, Tulchinsky E. The ability of Fos family members to produce phenotypic changes in epithelialoid cells is not directly linked to their transactivation potentials. *Oncogene*. Jul 18;21(31):4843-8. 2002

Moroz OV, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB. Multiple structural states of S100A12: A key to its functional diversity. *Microsc Res Tech*. Apr 15;60(6):581-92. 2003

Moroz OV, Antson AA, Grist SJ, Maitland NJ, Dodson GG, Wilson KS, Lukanidin E, Bronstein IB. Structure of the human S100A12-copper complex: implications for host-parasite defence. *Acta Crystallogr D Biol Crystallogr*. May;59(Pt 5):859-67. 2003

Celis JE, Gromov P, Gromova I, Moreira JM, Cabezon T, Ambartsumian N, Grigorian M, Lukanidin E, Thor Straten P, Guldberg P, Bartkova J, Bartek J, Lukas J, Lukas C, Lykkesfeldt A, Jaattela M, Roepstorff P, Bolund L, Orntoft T, Brunner N, Overgaard J, Sandelin K, Blichert-Toft M, Mouridsen H, Rank FE. Integrating Proteomic and Functional Genomic Technologies in Discovery-driven Translational Breast Cancer Research. *Mol Cell Proteomics*. Jun;2(6):369-77. 2003

Tkach V, Tulchinsky E, Lukanidin E, Vinson C, Bock E, Berezin V. Role of the Fos family members, c-Fos, Fra-1 and Fra-2, in the regulation of cell motility. *Oncogene*. Aug 7;22(32):5045-54. 2003